Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: March 2026 (Event date: March 10, 2026; Filing date: March 11, 2026)
Principal Executive Office: Herzliya, Israel
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions rather than financial performance.
Material Changes
- Shareholder Approval: On March 10, 2026, shareholders approved a resolution to amend the Company's articles of association.
- Capital Structure: The amendment authorizes an increase in the Company's registered share capital.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to disclose the outcome of the Special Meeting of Shareholders.
Investor Verification Checklist
- Verify the specific amount of the increase in registered share capital approved by shareholders.
- Confirm the effective date of the amended articles of association.
- Review subsequent filings for details on the utilization of the increased share capital (e.g., new equity issuances).